Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Cash from Investing Activities (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Cash from Investing Activities for 11 consecutive years, with $27.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities fell 81.83% to $27.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $228.0 million, a 81.6% increase, with the full-year FY2025 number at $228.0 million, up 81.6% from a year prior.
  • Cash from Investing Activities was $27.5 million for Q4 2025 at Intellia Therapeutics, up from -$741000.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $151.6 million in Q4 2024 to a low of -$399.4 million in Q3 2021.
  • A 5-year average of -$3.4 million and a median of $16.7 million in 2024 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: crashed 357.51% in 2023, then surged 1498.51% in 2025.
  • Intellia Therapeutics' Cash from Investing Activities stood at -$159.1 million in 2021, then soared by 81.05% to -$30.2 million in 2022, then surged by 252.36% to $45.9 million in 2023, then surged by 229.93% to $151.6 million in 2024, then tumbled by 81.83% to $27.5 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Cash from Investing Activities are $27.5 million (Q4 2025), -$741000.0 (Q3 2025), and $106.9 million (Q2 2025).